Journal of pharmacy practice最新文献_第6页

Intersecting Burdens: Type 2 Diabetes Diagnosis, Risk, and Pharmacological Management Among People Living With HIV. 交叉负担：2型糖尿病的诊断、风险和药物管理在HIV感染者中。

IF 1

Journal of pharmacy practice Pub Date : 2026-08-01 Epub Date: 2025-11-18 DOI: 10.1177/08971900251394121

Rachel Arnold, Briann Fischetti, Maria Longo

{"title":"Intersecting Burdens: Type 2 Diabetes Diagnosis, Risk, and Pharmacological Management Among People Living With HIV.","authors":"Rachel Arnold, Briann Fischetti, Maria Longo","doi":"10.1177/08971900251394121","DOIUrl":"10.1177/08971900251394121","url":null,"abstract":"Many patients living with human immunodeficiency virus (HIV) may develop long-term metabolic complications due to various reasons, such as chronic inflammation and adverse effects from antiretrovirals (ARVs). A particularly significant metabolic complication is type 2 diabetes (T2DM); however, limited evidence is available regarding the management of this disease state among people living with HIV (PLWH). We review the available resources and evidence on the management of T2DM among PLWH. Diagnosis and monitoring of T2DM are slightly different from the general population as hemoglobin A1c may underestimate the level of glycemia PLWH experience. Although PLWH are typically not reported within landmark clinical trials for antidiabetic medications, treatment is likely similar to those without the virus. There are several drug-drug interactions to note between ARVs and antidiabetic medications with one of the most notable being between dolutegravir and metformin. This interaction requires the maximum daily dose of metformin to be reduced. Additionally, modifications may be considered to a patient's ARV regimen in order to reduce metabolic disturbances as these medications may affect fat redistribution, lipids, weight, and insulin resistance. This review article is intended to aide clinicians in clinical decision making when treating PLWH diagnosed with T2DM.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"355-366"},"PeriodicalIF":1.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145549824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fournier's Gangrene Associated With Ertugliflozin. 与埃图列净相关的富尼耶坏疽。

IF 1

Journal of pharmacy practice Pub Date : 2026-08-01 Epub Date: 2025-07-28 DOI: 10.1177/08971900251364050

Megan Kunka Fritz

引用次数: 0

Evaluation of Antibiotic Selection in the Emergency Department Following the Implementation of an Infectious Source-Specific Order Set. 实施传染源特异性医嘱集后急诊科抗生素选择评估

IF 1

Journal of pharmacy practice Pub Date : 2026-08-01 Epub Date: 2025-11-03 DOI: 10.1177/08971900251394123

Jon Derringer, Cody Null, Jared Heiles, Katherine Lusardi, Amanda Novack, Ryan Dare

{"title":"Evaluation of Antibiotic Selection in the Emergency Department Following the Implementation of an Infectious Source-Specific Order Set.","authors":"Jon Derringer, Cody Null, Jared Heiles, Katherine Lusardi, Amanda Novack, Ryan Dare","doi":"10.1177/08971900251394123","DOIUrl":"10.1177/08971900251394123","url":null,"abstract":"Emergency department (ED) practitioners frequently prescribe antibiotics for sepsis and other infections, with quality and performance metrics often influencing broad-spectrum antibiotic selection. This study objective was to evaluate improvements in antibiotic selection in the ED following implementation and revision of sepsis order sets designed to adhere to Centers for Medicare and Medicaid Services sepsis performance measure bundle across time periods. This single-center, retrospective analysis assessed antibiotic orders in the ED across three periods of order set availability: no sepsis order set (period 1), general broad-spectrum order set (period 2), and infectious-source specific order set (period 3). Order rates of narrow-spectrum β-lactams, extended-spectrum cephalosporins, antipseudomonal β-lactams, fluoroquinolones, clindamycin, and other agents were assessed. Individual patient encounters with antibiotic orders for period 1 (n = 4228), period 2 (n = 4407), and period 3 (n = 5129) were assessed. Order set use for antibiotic ordering increased across time periods (4% vs 20.6% vs 53.3%; P < 0.001). Period 3 was associated with an increase in narrow spectrum β-lactam use (3% vs 3% vs 15.2%; P < 0.001), a decrease in antipseudomonal β-lactam use (30.1% vs 36.1% vs 27.7%; P < 0.001), and a decrease in targeted antibiotics associated with high risk for adverse effects (28% vs 16% vs 6.9%; P < 0.001). The creation and utilization of an infectious source-specific sepsis antibiotic order set was associated with improved antibiotic ordering trends in the emergency department. This intervention should be considered by hospital antimicrobial stewardship programs.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"309-314"},"PeriodicalIF":1.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145431695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enteral Feeding Tube Administration of Oral Sirolimus Tablets in a Critically Ill Adult. 危重成人口服西罗莫司片的肠内喂养管管理。

IF 1

Journal of pharmacy practice Pub Date : 2026-08-01 Epub Date: 2025-07-28 DOI: 10.1177/08971900251364068

Jordan N Livingston, Sarah S Harlan, Dmitry M Yaranov, Julie E Farrar

{"title":"Enteral Feeding Tube Administration of Oral Sirolimus Tablets in a Critically Ill Adult.","authors":"Jordan N Livingston, Sarah S Harlan, Dmitry M Yaranov, Julie E Farrar","doi":"10.1177/08971900251364068","DOIUrl":"10.1177/08971900251364068","url":null,"abstract":"Sirolimus is an immunosuppressive agent for solid organ transplant recipients and is commercially available as an oral tablet and liquid solution. Current package labeling does not support crushing tablets for administration via feeding tubes. A 72 year old white male presented to the trauma intensive care unit after a motor vehicle crash with a reported history of an orthotopic cardiac transplantation on maintenance sirolimus and prednisone, both of which were resumed on hospital day 1. During admission, the patient required intubation with placement of a nasogastric tube (NG) due to worsening respiratory status. Sirolimus was subsequently given by crushing the tablet and administering via the NG tube. Prior to sirolimus resumption on hospital day 1, a baseline sirolimus level resulted as 2.4 ng/mL and repeat trough levels of 1.7 ng/mL and 2.1 ng/mL were obtained on hospital days 17 and 24, respectively. The patient was discharged to a long term care facility after placement of a tracheostomy and percutaneous endoscopic gastrostomy (PEG) tube with orders to continue maintenance sirolimus and prednisone administered crushed via PEG tube. This report describes a novel administration method of sirolimus in a critically ill adult with detectable sirolimus levels throughout admission. This administration technique appears to be safe and warrants further investigation as a potentially efficacious alternative to standard oral administration.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"339-341"},"PeriodicalIF":1.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Cefdinir and Cephalexin as Step-Down Therapy in Pyelonephritis or Urosepsis. 头孢地尼与头孢氨苄降压治疗肾盂肾炎或尿脓毒症的比较。

IF 1

Journal of pharmacy practice Pub Date : 2026-08-01 Epub Date: 2025-10-29 DOI: 10.1177/08971900251393439

Andrew R Miesner, Jonathan R Hurdelbrink, Sarah M Wall, Geoffrey C Wall

{"title":"Comparison of Cefdinir and Cephalexin as Step-Down Therapy in Pyelonephritis or Urosepsis.","authors":"Andrew R Miesner, Jonathan R Hurdelbrink, Sarah M Wall, Geoffrey C Wall","doi":"10.1177/08971900251393439","DOIUrl":"10.1177/08971900251393439","url":null,"abstract":"Background: Cephalosporins are increasingly used to treat severe urinary tract infections (sUTI) due to rising resistance with standard antibioics. When switching from intravenous to oral cephalosporins there is limited clinical outcome data to guide selection. Objective: To compare the failure rate between cephalexin and cefdinir when used as oral step-down therapy in sUTI. Methods: In this retrospective study, we assessed patients admitted to 3 hospitals for sUTI over a 1-year period. Cases were identified using ICD-10 codes N10, N39.0, and A41.9. Patients who received intravenous antibiotics for >24 hours and completed treatment with cephalexin or cefdinir were included. The primary composite outcome was death, rehospitalization for UTI in 30 days, unplanned clinic or emergency visit for UTI in 30 days, hospitalization for any reason in 90 days, or Clostridoides difficile infection. Secondary outcomes included each individual composite outcome element. Results: Overall, 75 cefdinir and 135 cephalexin cases were included. Patients were similar in baseline characteristics. Pyelonephritis occurred among the cephalexin group (30.2% vs 46.7%, P = 0.024). Composite failure occurred in 8% of patients receiving cefdinir and 14.1% receiving cephalexin (P = 0.193). Secondary outcomes did not differ except clinic or emergency visit for UTI was lower among patients receiving cefdinir than cephalexin (0% vs 7.2%; P = 0.028). Logistic regression revealed no significant variable associations with treatment failure, except for cephalexin use, which was associated with clinic or emergency visit for UTI (r2 = 0.075). Conclusions: Treatment failure rates did not differ between cefdinir and cephalexin; however, patients receiving cephalexin had more unplanned clinic and emergency visits.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"297-302"},"PeriodicalIF":1.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145401259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the Link Between Intravenous Methocarbamol and Acute Kidney Injury. 探讨静脉注射甲氨氨基酚与急性肾损伤的关系。

IF 1

Journal of pharmacy practice Pub Date : 2026-08-01 Epub Date: 2025-10-28 DOI: 10.1177/08971900251394101

Matthew Li, Avery Wilson, Phillip Dudley, Tyler D'agostino, Darrel Brennen, Anrew Villion, Matthew Bronstein

{"title":"Exploring the Link Between Intravenous Methocarbamol and Acute Kidney Injury.","authors":"Matthew Li, Avery Wilson, Phillip Dudley, Tyler D'agostino, Darrel Brennen, Anrew Villion, Matthew Bronstein","doi":"10.1177/08971900251394101","DOIUrl":"10.1177/08971900251394101","url":null,"abstract":"Background: Methocarbamol is a central nervous system depressant with antispasmodic properties used as a skeletal muscle relaxant as part of a multimodal analgesia regimen in critically ill patients. Intravenous (IV) methocarbamol contains polyethylene glycol (PEG) 300 and propylene glycol (PG) which have been associated with acute kidney injury (AKI). To mitigate AKI risk, IV methocarbamol is limited to 72 consecutive hours, followed by a 48-hour drug-free interval (DFI). Objective: To characterize the incidence of AKI in intensive care unit (ICU) patients receiving IV methocarbamol. Methods: This is a single-center, retrospective evaluation of adult trauma or surgical ICU patients who received at least 3 consecutive doses of IV methocarbamol. The primary outcome was the difference in SCr from day 1 through day 7 after IV methocarbamol initiation. Results: A total of 68 patients met inclusion criteria. Four patients were classified in the non-DFI group. There was no difference in the median (IQR) SCr (mg/dL) measured at any time point from day 1 through day 7 after IV methocarbamol initiation in the entire cohort [0.83 (0.71, 1.08) vs 0.74 (0.62, 1.33), P = 0.55]. There was no difference between the median (IQR) SCr (mg/dL) from day 1 through day 7 in patients that had no DFI [1.04 (0.89, 2.56) vs 1.20 (0.79, 2.92), P = 0.84]. Conclusion: No statistically significant change in SCr was observed over time in critically ill patients receiving IV methocarbamol regardless of DFI use.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"330-334"},"PeriodicalIF":1.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145390577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of Intravenous Buprenorphine for Acute Pain in Critically Ill Patients in a Medical Intensive Care Unit. 丁丙诺啡静脉注射治疗重症病人急性疼痛的疗效观察

IF 1

Journal of pharmacy practice Pub Date : 2026-08-01 Epub Date: 2025-09-30 DOI: 10.1177/08971900251384153

Kennedi Satterfield, Jessica L Elefritz, Kyle Quirk, Jennica Johns, Sarah Ehrman, Eric M McLaughlin, Brookeanne Magrum

{"title":"Efficacy of Intravenous Buprenorphine for Acute Pain in Critically Ill Patients in a Medical Intensive Care Unit.","authors":"Kennedi Satterfield, Jessica L Elefritz, Kyle Quirk, Jennica Johns, Sarah Ehrman, Eric M McLaughlin, Brookeanne Magrum","doi":"10.1177/08971900251384153","DOIUrl":"10.1177/08971900251384153","url":null,"abstract":"Background: Buprenorphine is an opioid that has recently gained interest for acute pain management in post-operative patients. It has theoretical advantages due to its unique mechanism and favorable adverse effect profile. Currently, no studies have evaluated intravenous buprenorphine for acute pain management in a critically ill medical patient population.Objective: The objective of this study was to compare the use of intravenous buprenorphine with or without a full agonist IV opioid vs a full agonist IV opioid alone for acute pain in non-ventilated, non-surgical critically ill patients.Methods: A retrospective cohort study was completed of patients who received IV buprenorphine or full-agonist opioids while admitted to the medical intensive care unit at an academic medical center and community hospital.Results: The median DVPRS difference in the buprenorphine group compared to the control group was 5 vs 6. The non-inferiority t-test showed buprenorphine was not significantly non-inferior with mean DVPRS score at day 3 for the buprenorphine group was 5.02 and the control group was 5.07 (P = 0.85). Respiratory depression within 7 days occurred less in the buprenorphine group (20.6% vs 42.9%, P = 0.004). Oversedation occurred less in the buprenorphine group (27% vs 46.8%, P = 0.01. The ICU LOS was longer in the buprenorphine group (8 vs 5 days, P = 0.01). The median daily OME on day 1 was less in the buprenorphine group (29 vs 42.5, P = 0.03).Conclusion: Intravenous buprenorphine may be a comparable alternative to full agonist intravenous opioids for pain control in the medical intensive care unit.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"271-279"},"PeriodicalIF":1.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Changing Migraine Outcome on Pharmacist Interventions in a Health-System Specialty Pharmacy. 改变偏头痛结局对卫生系统专业药房药师干预的影响。

IF 1

Journal of pharmacy practice Pub Date : 2026-07-16 DOI: 10.1177/08971900261469298

Megan Markesbery, Emily O'Reilly, Chelsey McPheeters

{"title":"Impact of Changing Migraine Outcome on Pharmacist Interventions in a Health-System Specialty Pharmacy.","authors":"Megan Markesbery, Emily O'Reilly, Chelsey McPheeters","doi":"10.1177/08971900261469298","DOIUrl":"https://doi.org/10.1177/08971900261469298","url":null,"abstract":"Health-system specialty pharmacies (HSSPs) provide specialized medication therapy management to patients with complex medical conditions. HSSPs assess clinical outcomes for specialty disease states, including migraines. There are currently no studies comparing types of outcomes for patients with migraines and the impact on pharmacist intervention in HSSPs. The aim of this study was to determine if changing migraine outcome from a non-disease specific patient reported outcome measure (PROM) to a disease specific patient reported outcome (PRO) impacts the number of pharmacist interventions made on migraine regimens in a HSSP. A single-center, pre-post, retrospective chart review was conducted at a HSSP. Adult patients who received at least one abortive specialty migraine medication and/or at least three preventative specialty migraine medication fills were included in the study. The primary endpoint was the number of pharmacist interventions regarding pharmacologic migraine regimens before and after the outcome change. Key secondary endpoints included change in number of migraine days per month, change in number of missed days from school, work or planned activities, number of migraine episodes requiring hospitalization, and overall number of pharmacist interventions. There were 61 patients included in the study. The number of pharmacist interventions on migraine regimens was no difference between the migraine PROs group (15.2%) when compared to the PROM group (13.5%; P = 0.715). Utilizing either non-disease specific PROM or disease-specific PROs as a clinical outcome measure for HSSP migraine patients could be valuable, with the latter shifting pharmacist interventions toward migraine pharmacotherapy optimization.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261469298"},"PeriodicalIF":1.0,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148471395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Low Statin Use Post-liver Transplant Despite Increased Rates of Dyslipidemia. 肝移植后低他汀类药物的使用，尽管血脂异常率增加。

IF 1

Journal of pharmacy practice Pub Date : 2026-07-13 DOI: 10.1177/08971900261469304

Sarah Blocker, Molly Henry, Mary Leick

{"title":"Low Statin Use Post-liver Transplant Despite Increased Rates of Dyslipidemia.","authors":"Sarah Blocker, Molly Henry, Mary Leick","doi":"10.1177/08971900261469304","DOIUrl":"https://doi.org/10.1177/08971900261469304","url":null,"abstract":"Previous literature has demonstrated that hyperlipidemia is common post-transplant; however, low statin utilization has been seen post-liver transplant. Furthermore, assessment of statin qualification in this setting is limited. This study's objective was to evaluate the incidence of hyperlipidemia and determine the rate of qualification for and initiation of statin therapy in liver transplant recipients to better characterize the complication and associated clinical practice behaviors. This single center, retrospective cohort study included adult patients who received an isolated liver transplant between January 1, 2015 and June 30, 2019 and had lipid panels within 15 months pre- and post-transplant. The dual primary outcomes were the incidences of hyperlipidemia and statin qualification, as determined by 2012 AASLD and 2018 ACC/AHA guidance. Secondary outcomes included statin use and tolerability, hypertriglyceridemia, and immunosuppression factors. Of the 282 patients screened, 79 patients were included. Compared to pre-transplant, incidences of hyperlipidemia and statin qualification were both increased post-transplant (hyperlipidemia: 21.5% vs 49.4%, P = 0.0003; statin qualification: 46.8% vs 64.6%, P = 0.025). Of the 51 statin-qualifying patients post-transplant, twenty-two (43%) received statin therapy. One patient experienced muscle aches requiring statin discontinuation. Hypertriglyceridemia was more common post-transplant than pre-transplant (11.4% vs 60.8%, P < 0.0001). Of patients on tacrolimus, 58% qualified for statin therapy compared to 93% of patients on an mTOR inhibitor. Nearly two-thirds of liver transplant recipients qualify for statin therapy post-transplant. Despite increased rates of dyslipidemia and statin qualification post-liver transplant, statin therapy remains underutilized. Optimization of lipid management remains an area of need post-liver transplant.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261469304"},"PeriodicalIF":1.0,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148437001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of a Specialized Pharmacist-Managed Gout Clinic in a Veteran Population. 在退伍军人群体中由专业药剂师管理的痛风诊所的评价。

IF 1

Journal of pharmacy practice Pub Date : 2026-07-08 DOI: 10.1177/08971900261468840

Brian S Chen, My-Hanh N Nguyen, Timothy C Chen

{"title":"Evaluation of a Specialized Pharmacist-Managed Gout Clinic in a Veteran Population.","authors":"Brian S Chen, My-Hanh N Nguyen, Timothy C Chen","doi":"10.1177/08971900261468840","DOIUrl":"https://doi.org/10.1177/08971900261468840","url":null,"abstract":"Background: Gout is the most common inflammatory arthritis, and the underlying cause of gout, chronic elevation of serum uric acid (sUA), is well understood. Despite this, only a minority of patients receive optimal therapy as it requires adherence to frequent lab monitoring and urate lowering therapy (ULT) titration to achieve target goals. Objective: To evaluate the effectiveness of the pharmacist-managed gout clinic at VA San Diego Healthcare System (VASDHS) in lowering sUA. Methods: This was a single center, retrospective chart review of all Veterans enrolled in the pharmacy gout clinic from January 1, 2017, to December 31, 2021, comparing baseline and final sUA. The primary outcome was reduction of sUA from baseline. Results: There was statistically significant reduction of sUA from baseline at months 3, 6, 9, and 12, with average sUA levels of 6.8 ± 1.7 mg/dL, 6.4 ± 1.5 mg/dL, 6.0 ± 1.6 mg/dL, and 6.1 ± 2.2 mg/dL, respectively (P < 0.001 for all values). Conclusion: This study suggests that the pharmacist-managed gout clinic can effectively lower and maintain sUA levels through the treat-to-target approach. Though the results of this study showed statistically significant sUA reduction, most patients did not reach their sUA goals by the end of the study. However, this finding may not be clinically relevant as patients can be above their sUA goal and still be gout flare free or have low frequency of flares.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261468840"},"PeriodicalIF":1.0,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148411620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0